Lupin Shares Trade Flat Despite Exclusive China Pact for Diabetes, Obesity Drug

Shares of Lupin Ltd are trading flat on 30th December after touching a day’s high of Rs 2,098.80, despite the company saying it has inked an exclusive licensing, supply, and distribution agreement for a GLP-1 drug.

Lupin has entered into an exclusive licensing, supply, and distribution agreement with China-based Gan & Lee Pharmaceuticals for Bofanglutide. Under this deal, Lupin will have exclusive rights to commercialise and distribute the drug in India.

Bofanglutide is a GLP-1 injectable given once every two weeks. It is used for the treatment of Type 2 diabetes and weight management, offering a longer dosing gap compared to existing therapies.

According to Lupin, the drug is potentially first-in-class globally. Clinical data suggest that its weight-loss effectiveness is comparable to, or better than, that of currently available GLP-1 drugs.

A key advantage of Bofanglutide is its less frequent dosing schedule. Unlike most GLP-1 treatments that require weekly injections, this drug needs to be taken only once every two weeks.

Overall, the agreement strengthens Lupin’s diabetes treatment portfolio and helps fast-track its entry into the growing obesity treatment segment.

At 10:35 AM, shares of Lupin were trading 0.15% higher at Rs 2,085.30 on NSE.

Ready to invest like a pro? Tradz by EquityPandit equips you with 100+ Free tools and knowledge you need to succeed. Download the Tradz app and gain access to daily stock lists and insightful market analysis and much more!

The post Lupin Shares Trade Flat Despite Exclusive China Pact for Diabetes, Obesity Drug appeared first on Equitypandit.